simendan has been researched along with Coronary Artery Disease in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Álvarez-Castillo, A; Ferrer-Rodríguez, J; García-González, MJ; Iribarren-Sarrías, JL; Jiménez-Rivera, JJ; Jorge-Pérez, P; Lacalzada-Almeida, J; Martínez-Sanz, R; Montoto-López, J; Pérez-Hernández, R | 1 |
| Akchurin, RS; Dzybinskaya, EV; Gazizova, VP; Gramovich, VV; Shiryaev, AA; Stukalova, OV; Vlasova, EE | 1 |
| Alexander, JH; Anstrom, KJ; Argenziano, M; Cowper, PA; Duncan, AE; Fremes, S; Goodman, SG; Heringlake, M; Jankowich, R; Knight, JD; Leimberger, JD; Levy, JH; Lopes, RD; Luber, J; Mark, DB; Mehta, RH; Nagpal, AD; Teoh, K; Toller, W; van Diepen, S | 1 |
| Bishnoi, A; Gandhi, H; Gandhi, S; Garg, P; Malhotra, A; Sharma, P | 1 |
| Abacilar, AF; Akpinar, MB; Alayunt, EA; Ates, M; Gul, I; Okur, FF; Sahin, V; Tavli, T; Uc, H; Uyar, IS | 1 |
| Hote, M; Kiran, U; Malik, V; Subramanian, A | 1 |
| Anastasiadis, K; Antonitsis, P; Argiriadou, H; Asteriou, C; Grosomanidis, V; Kleontas, A; Tossios, P; Vranis, K | 1 |
| Kurt, IH | 1 |
| Baddour, AJ; Tagarakis, GI; Tsilimingas, NB | 1 |
| Boboshko, VA; Cherniavskiy, AM; Karaskov, AM; Kornilov, IA; Lomivorotov, VN; Lomivorotov, VV | 1 |
| Boboshko, VA; Chernyavskiy, AM; Efremov, SM; Karaskov, AM; Knazkova, LG; Kornilov, IA; Lomivorotov, VN; Lomivorotov, VV | 1 |
| De Santis, V; Mazzesi, G; Miraldi, F; Ozdem, SS; Papalia, U; Puddu, PE; Tritapepe, L; Usta, C; Vitale, D | 1 |
| Harjola, VP; Siirilä-Waris, K; Suojaranta-Ylinen, R | 1 |
| Flaim, BD; MacIsaac, AI; Prior, DL; Yii, MY | 1 |
1 review(s) available for simendan and Coronary Artery Disease
| Article | Year |
|---|---|
Use of levosimendan in patients with ischemic heart disease following mechanical reperfusion.
Topics: Cardiotonic Agents; Coronary Artery Disease; Humans; Hydrazones; Myocardial Ischemia; Myocardial Reperfusion; Myocardial Stunning; Pyridazines; Simendan; Vasodilator Agents | 2009 |
8 trial(s) available for simendan and Coronary Artery Disease
| Article | Year |
|---|---|
Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery.
Topics: Aged; Cardiotonic Agents; Coronary Artery Bypass; Coronary Artery Disease; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Female; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Hospital Costs; Humans; Male; Middle Aged; Postoperative Complications; Risk Assessment; Risk Factors; Simendan; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |
Preoperative levosimendan in ischemic mitral valve repair.
Topics: Adult; Aged; Cardiopulmonary Bypass; Cardiotonic Agents; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Heart Valve Prosthesis Implantation; Hemodynamics; Humans; Hydrazones; India; Intensive Care Units; Length of Stay; Male; Middle Aged; Mitral Valve Annuloplasty; Mitral Valve Insufficiency; Postoperative Complications; Preoperative Care; Prospective Studies; Pyridazines; Respiration, Artificial; Simendan; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
Evaluation of myocardial contractility determination with tissue tracking echocardiography after levosimendan infusion in patients with poor left ventricular function and hemodynamics.
Topics: Cardiotonic Agents; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Disease; Echocardiography; Elasticity Imaging Techniques; Female; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Reproducibility of Results; Sensitivity and Specificity; Simendan; Treatment Outcome; Ventricular Dysfunction, Left | 2014 |
Effect of Levosimendan on Diastolic Function in Patients Undergoing Coronary Artery Bypass Grafting: A Comparative Study.
Topics: Aged; Blood Pressure; Coronary Artery Bypass; Coronary Artery Disease; Diastole; Double-Blind Method; Female; Humans; Hydrazones; Male; Middle Aged; Postoperative Complications; Prospective Studies; Pyridazines; Simendan; Treatment Outcome; Vasodilator Agents | 2015 |
Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study.
Topics: Cardiac Output, Low; Cardiotonic Agents; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Finland; Follow-Up Studies; Humans; Hydrazones; Incidence; Infusions, Intravenous; Male; Middle Aged; Pilot Projects; Postoperative Complications; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Survival Rate; Tomography, Emission-Computed, Single-Photon; Ventricular Dysfunction, Left; Ventricular Function, Left | 2016 |
Levosimendan vs. intra-aortic balloon pump in high-risk cardiac surgery.
Topics: Aged; Biomarkers; Cardiopulmonary Bypass; Cardiotonic Agents; Chi-Square Distribution; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Diseases; Hemodynamics; Humans; Hydrazones; Intra-Aortic Balloon Pumping; Male; Middle Aged; Pyridazines; Risk Assessment; Risk Factors; Russia; Simendan; Stroke Volume; Treatment Outcome; Troponin I; Ventricular Function, Left | 2011 |
Levosimendan versus an intra-aortic balloon pump in high-risk cardiac patients.
Topics: Aged; Cardiopulmonary Bypass; Cardiotonic Agents; Coronary Artery Disease; Female; Hemodynamics; Humans; Hydrazones; Intensive Care Units; Intra-Aortic Balloon Pumping; Length of Stay; Male; Middle Aged; Prospective Studies; Pyridazines; Simendan; Troponin I | 2012 |
Levosimendan in cardiac surgery.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Artery Disease; Epinephrine; Female; Follow-Up Studies; Hemodynamics; Humans; Hydrazones; Male; Milrinone; Norepinephrine; Postoperative Care; Preoperative Care; Pyridazines; Risk Factors; Simendan; Time Factors; Vasoconstrictor Agents; Vasodilator Agents; Vasopressins; Ventricular Dysfunction, Left | 2005 |
5 other study(ies) available for simendan and Coronary Artery Disease
| Article | Year |
|---|---|
Preconditioning with levosimendan reduces postoperative low cardiac output in moderate-severe systolic dysfunction patients who will undergo elective coronary artery bypass graft surgery: a cost-effective strategy.
Topics: Aged; Cardiac Output, Low; Cardiotonic Agents; Coronary Artery Bypass; Coronary Artery Disease; Cost-Benefit Analysis; Elective Surgical Procedures; Female; Humans; Incidence; Male; Postoperative Complications; Simendan; Spain; Stroke Volume; Ventricular Function, Left | 2020 |
[The possibilities of using levosimendan in medical preparation to Coronary Artery Bypass Grafting in coronary artery disease patients with low left ventricular ejection fraction].
Topics: Coronary Artery Bypass; Coronary Artery Disease; Humans; Hydrazones; Postoperative Complications; Prospective Studies; Pyridazines; Retrospective Studies; Simendan; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |
Can pulmonary artery hypertension be attributed to levosimendan? A problematic based on a patient's case.
Topics: Aged; Aortic Valve Stenosis; Blood Pressure; Cardiotonic Agents; Coronary Artery Bypass; Coronary Artery Disease; Heart Valve Prosthesis Implantation; Humans; Hydrazones; Hypertension, Pulmonary; Pulmonary Artery; Pyridazines; Simendan | 2010 |
Comparision of the inotropic effects of levosimendan, rolipram, and dobutamine on human atrial trabeculae.
Topics: Adult; Aged; Cardiotonic Agents; Coronary Artery Disease; Dobutamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electric Stimulation; Female; Heart Atria; Heart Valve Diseases; Humans; Hydrazones; Male; Middle Aged; Myocardial Contraction; Pyridazines; Rheumatic Heart Disease; Rolipram; Simendan; Troponin C | 2004 |
Pre-operative use of levosimendan in two patients with severe aortic stenosis and left ventricular dysfunction.
Topics: Aged; Aortic Valve Stenosis; Cardiotonic Agents; Coronary Artery Bypass; Coronary Artery Disease; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Simendan; Ventricular Dysfunction, Left | 2006 |